2013 Archived Content
 

Engineering Stream

4th Annual
Engineering Bispecific Antibodies

The Future of Antibody Development

May 2-3, 2013

Bispecific and multiclonal antibodies are one of the most promising and exciting areas of protein engineering. The range of therapeutic uses for bispecific antibodies is expanding beyond oncology to target diseases of the immune system, heart and CNS. This meeting will discover the remaining challenges and creative problem solving that have been used to make successful bispecific formats. The latest solutions for improving efficacy and minimizing toxicity will be explored.

Scientific Advisory Board 

Michael J. Feldhaus, Ph.D., Founder and CEO, Arus Biologics
Nazzareno Dimasi, Ph.D., Senior Scientist, Antibody Discovery & Protein Engineering, MedImmune
Tariq Ghayur, Ph.D., Senior Research Fellow, Abbott Bioresearch Center
Christian Klein, Ph.D., Discovery Oncology oDTA, Pharma Research and Early Development (pRED), Roche Glycart AG
Robert Mabry, Ph.D., Associate Director, Antibody Discovery and Bispecific Engineering, Adimab, LLC

 

Day 1 | Day 2 | Download Brochure 


THURSDAY, MAY 2

12:30 pm Conference Registration


Opening Session 

1:30 Chairperson's Remarks

Christian KleinChristian Klein, Ph.D., Discovery Oncology oDTA, Pharma Research and Early Development (pRED), Roche Glycart AG

» 1:40 KEYNOTE PRESENTATION 

Ideas for Novel Targets and Target Pairs for Bispecific Antibody Approaches

William R. StrohlWilliam R. Strohl, Ph.D., Vice President, Biologics Research, Janssen Pharmaceuticals, Inc.

This presentation will address the ideas that novel targets will continue to fuel the discovery pipelines, bispecificity allows for combinations of targets pairs, allowing us to address multiple pathways simultaneously, and analysis of target biology in bispecifics will likely add to the complexity of discovery programs.


2:10 Bispecific Heterodimeric IgG Antibodies and the CrossMab Technology

Christian Klein, Ph.D., Discovery Oncology oDTA, Pharma Research and Early Development (pRED), Roche Glycart AG

An overview about bispecific heterodimeric IgG antibody formats will be presented along with applications of the crossMab technology. MonoMab & DuoMab novel antibody formats by antibody domain crossover will be discussed.

2:40 Designing and Engineering Azymetric™ Antibodies Towards Solving the "Light Chain Problem"

David Poon, Ph.D., Director, External R&D and Alliances, Zymeworks

A structure-guided computational engineering approach was successfully applied to introduce bispecific binding to human IgG1 antibodies with the heterodimerization of 2 different heavy chains plus the corresponding efficient association of their respective light chains. The resulting Azymetric™ bispecific antibodies retain favorable CMC properties and can target antigens via IgG1-like Fab domains. Novel mechanisms of action, enabled by the use of Azymetric™ antibodies, will be highlighted including T-cell engagement and the re-directed killing of tumors.

3:10 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 Problem Solving Breakout Discussions

Concurrent problem solving breakout discussions, open to all attendees, speakers, sponsors, and exhibitors, provide a forum for discussing key issues and meeting potential collaborators. Plan to take part and explore these topics in-depth. Please pick a topic of your choice, find your table and join in.

TABLE: Using Bispecifics for T Cell Recruitment and Activation

Moderator: Christoph Rader, Ph.D., Associate Professor, Department of Cancer Biology and Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida

   • What makes a good target for bispecifics?
   • Are there alternatives to recruiting and activating T cells via CD3/TCR?
   • Where does NK cell recruitment and activation by bispecifics stand?
   • Long vs. short circulatory half-life of bispecific antibodies – what do we want?
   • What are suitable animal models for investigating the activity and toxicity of bispecifics?

TABLE: Bispecific Antibodies in Infectious Diseases

Moderator:Charles (Ken) Stover, Ph.D., Senior Director, Discovery Infectious Disease, MedImmune

TABLE: Developability of Novel Formats

Moderator: Robert Mabry, Ph.D., Associate Director, Antibody Discovery and Bispecific Engineering, Adimab, LLC

   • Criteria for selecting antibodies to generate bispecifics
   • Benchmarks for upstream bioanalytics
   • Momentum behind IgG-like bispecific formats
   • Maintaining antibody fragment strategies as a viable path forward

TABLE: Novel Targets for Cancer Immunotherapy

Moderator: Christian Klein, Ph.D., Discovery Oncology oDTA, Pharma Research and Early Development (pRED), Roche Glycart AG

   • Current targets for cancer immunotherapies
   • Emerging targets for cancer immunotherapy
   • How will the new generation of immunomodulatory antibodies look like
   • ADCC enhanced antibodies, T cell bispecifics: experiences, advantages, disadvantages
   • Role of novel modalities: cancer vaccines, adoptive T cell therapy

5:00 End of Day



Day 1 | Day 2 | Download Brochure